A Standardized, 3-Tiered, Seizure Burden-Based Protocol for the Treatment of Neonatal Seizures

Ashley A Moeller1, Andrei R Stefanescu2, Beatrice M Stefanescu1

  • 1Indiana University School of Medicine, Indianapolis, IN, USA.

Insights

A new protocol for treating neonatal seizures in the neonatal intensive care unit (NICU) reduced midazolam use and electroencephalography (EEG) monitoring duration, improving short-term outcomes.

Area of Science:

  • Neonatal Neurology
  • Clinical Protocol Development
  • Pediatric Epilepsy

Background:

  • Neonatal seizures are a common neurological emergency requiring prompt and effective treatment.
  • Current treatment protocols vary, potentially leading to suboptimal seizure control and medication side effects.
  • Standardizing seizure management is crucial for improving patient outcomes in the neonatal intensive care unit (NICU).

Purpose of the Study:

  • To evaluate the effectiveness of a standardized, 3-tiered, seizure burden-based protocol for treating electroencephalography (EEG)-confirmed neonatal seizures.
  • To assess the impact of the protocol on short-term outcomes in infants admitted to a level IV NICU.

Main Methods:

  • A prospective study design comparing outcomes before and after protocol implementation.
  • Enrollment of 107 infants with EEG-confirmed seizures in the NICU over a 25-month period.
  • Analysis of medication use (midazolam infusions), EEG monitoring duration, and hospital length of stay.

Main Results:

  • Midazolam infusion use decreased by 53.7% (p=0.02) after protocol implementation.
  • Duration of EEG monitoring was significantly reduced from 5 to 3 days (p=0.005).
  • Hospital length of stay remained unchanged; however, midazolam infusion duration showed a non-significant increase when excluding outliers.

Conclusions:

  • Implementation of a standardized, 3-tiered protocol effectively improved short-term outcomes for neonatal seizures.
  • Reduced EEG duration and midazolam use suggest a decreased overall seizure burden.
  • Further research is warranted to determine the long-term neurodevelopmental effects of this protocol.
Abstract

Related Concept Videos

Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
486
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
234
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
725
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
371